Microbiological Profile of Fracture Related Infection at a UK Major Trauma Centre

Kavi H Patel1, Laura I Gill2, Elizabeth K Tissingh1

  • 1Limb Reconstruction and Bone Infection Service, The Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London E1 1FR, UK.

PubMed

Insights

Fracture Related Infections (FRI) are a major surgical challenge. This study analyzed 330 FRI cases, identifying common bacteria like Staphylococcus aureus and Pseudomonas aeruginosa, to guide antibiotic treatment strategies.

Area of Science:

  • Orthopaedic Surgery
  • Infectious Diseases
  • Microbiology

Background:

  • Fracture Related Infection (FRI) poses significant challenges in Trauma and Orthopaedic surgery.
  • Understanding the microbiological landscape of FRI is crucial for effective treatment and improved patient outcomes.

Purpose of the Study:

  • To determine the microbiological profile of FRI cases treated over a six-year period.
  • To correlate findings with current antibiotic protocols and diagnostic methods.
  • To provide data from one of Europe's busiest trauma centers.

Main Methods:

  • Retrospective analysis of adult FRI cases treated between 2016 and 2021.
  • Collection of data on patient demographics, diagnostics, causative organisms, and antibiotic susceptibilities.
  • Identification of 463 potentially pathogenic organisms from 330 infection episodes.

Main Results:

  • The most common pathogens were Staphylococcus aureus (24.4%), coagulase-negative Staphylococci (14%), Pseudomonas aeruginosa (8.2%), Enterobacter species (7.8%), and Escherichia coli (6.9%).
  • Polymicrobial infections occurred in 33.6% of cases; no organism was identified in 17.5%.
  • Resistant organisms were found in 3.3% (gram-positive) and 13.6% (gram-negative) of episodes.

Conclusions:

  • The identified microbiological patterns in FRI should inform empirical antibiotic choices for prophylaxis and treatment.
  • The study provides the largest single-center cohort of FRIs from a major trauma center.
  • Empirical antibiotic choices of teicoplanin and meropenem would cover 96.3% of cultured organisms.